Independent real-world evidence for healthcare services and the pharmaceutical industry.


Brand stripe

Our specialist knowledge and operational experience over more than 20 years enable us to deliver real-world evidence to improve understanding of treatment effectiveness and safety and guide better decision-making in healthcare.

Our work has supported applications to reimbursement authorities including the National Institute for Health and Care Excellence (NICE), All Wales Medicines Strategy Group (AWMSG), Scottish Medicines Consortium (SMC), and equivalent European regulatory bodies.

We have published more than 200 papers and abstracts in peer-reviewed journals, all of which can be viewed in our Publications section.

Our clients include Adelphi, Aimmune Therapeutics, Alexion, Alimera Sciences, Astellas, AstraZeneca, Diurnal, Eisai, Grunenthal, KRKA, MedImmune, Merck, Norgine, Novartis, Pfizer, Reckitt Benckiser, Sanofi-Aventis, Shionogi, Shire, Takeda and the NHS.

Pharmacoepidemiology and Risk Management

Brand stripe

We design, conduct and support many types of project, including retrospective observational studies and prospective registries, to help you understand disease distribution, burden of illness, risk factors, treatment patterns, effectiveness and safety.

Health Economics and Outcomes Research

Brand stripe

We recognise that reimbursement authorities need real-world data to make crucial decisions about drugs and other treatments. We conduct high-quality studies to deliver health economic evidence, including burden of illness, comparative effectiveness, and economic value analyses.

Interpretation and Reporting

Brand stripe

We not only analyse data on our client’s behalf but interpret results and prepare findings for wider dissemination.

Recent Publications

Brand stripe

Non-Response to Antibiotic Treatment in Adolescents for Four Common Infections in UK Primary Care 1991-2012: A Retrospective, Longitudinal Study

Berni E, Scott LA, Jenkins-Jones S, De Voogd H, Rocha MS, Butler CC, Morgan CL, Currie CJ

Read more »

Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe

Holden SE, Currie CJ, Lennon M, Reynolds AV, Moots RJ

Read more »

Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study

Holden SE, Jenkins-Jones S, Currie CJ

Read more »